Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Pharmagen to Present Strategic Vision for Solving Nation's Parenteral Drug Shortage Crisis at 2013 BIO International Convention



  Pharmagen to Present Strategic Vision for Solving Nation's Parenteral Drug
             Shortage Crisis at 2013 BIO International Convention

PR Newswire

SILVER SPRING, Md., April 22, 2013

SILVER SPRING, Md., April 22, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB:
PHRX) (the "Company" or "Pharmagen") is excited to announce that it will
present its strategic vision for solving the Nation's parenteral drug shortage
crisis at the 2013 Biotechnology Industry Organization (BIO) International
Convention held in Chicago, Illinois on April 23, 2013. The presentation will
be given at the North Carolina Pavilion, Booth #2617, at 4:00 pm local time.

Pharmagen, in conjunction with biopharmaceutical industry leaders BioPlan
Associates and Kymanox, will release the results of a comprehensive market
analysis of the Nation's parenteral drug shortage crisis and outline a
revolutionary supply chain and production methodology to address the problem.
BioPlan Associates has identified that shortages cost US health providers well
over $216 million annually in extra labor to simply manage; these shortages
also pose serious risks to successful and expedient patient outcomes. The
concern for patient safety is at the forefront of health policy after the 2012
Meningitis Outbreak and the Food & Drug Administration (FDA) has been looking
for solutions to combat the shortage epidemic. Supply issues are expected to
continue and Pharmagen estimates that the total market opportunity approaches
$1 billion as US baby boomers are aging. Kymanox, a specialty process
engineering and regulatory compliance company, has bundled a suite of new
production methodologies that will allow Pharmagen to leverage its proprietary
knowledge of drug shortages and translate it into cGMP, FDA-approved products
that will fill critical supply gaps. This novel approach – coupled with a
newly coined concept known as cGMP +® – will allow Pharmagen to produce the
highest quality sterile injectables on the market today.

"We've spent the last 6 months studying this issue with some of the brightest
minds in the pharmaceutical business. The buy-in from our partners and the
enthusiastic encouragement from our customers is validation that there's an
enormous opportunity here. Our plan is predicated on a bottom-up approach that
allows us to leverage our intricate knowledge of the shortage market with an
FDA-approved facility that can turn out finished drugs in a matter of days,
not months. Our ability to connect a dynamic market with what's been
traditionally a slow manufacturing ecosystem is what makes us special. Given
this positioning, there isn't another company out there that can do what we
do," said Mackie A. Barch, CEO of Pharmagen.

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating
divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and
Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the
nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen
is meeting the demand of health provider market through dynamic, independent
wholesale, compounding, and innovative IT solutions.  Nationally focused,
Pharmagen is a dynamic distributor of specialty drugs, compounding and admix
pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the
healthcare provider market. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are hard-to-find due to
drug manufacturers' production shortages.

About Kymanox

Kymanox, with headquarters now in RTP, North Carolina, is a premier technical
products and technical project management company. We have expertise in
providing engineering, scientific, and regulatory support to companies
involved in Biopharmaceutical, Medical Device, and Nanotechnology development.
Kymanox has a proven track record in solving complex scale-up, technology
transfer, and manufacturing problems – as well as receiving positive feedback
from the FDA on executing complex approval pathways for next generation
drugs.  With our focus on commercialization, Kymanox helps bring new products
to patients in need.

About BioPlan Associates

BioPlan Associates is a strategic marketing and marker research consultancy,
providing analysis to biotech and pharma companies for over 20 years. BioPlan
helps their clients understand market and customers' needs. This is especially
important in fast-moving biotechnology, life sciences, and health sciences
markets. They Deliver confidence. Their clients' decisions are based on
customer needs. Their technology clients get the decision-making tools and
actionable information they need to make decisions today.  BioPlan supports
biopharmaceutical, biotech, diagnostics, and life sciences suppliers seeking
customer needs analysis need to make smart decisions.

Contact:  888-264-4597 or info@pharmagenrx.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
The words "forecast", "anticipate", "estimate", "project", "intend", "expect",
"should", "believe", and similar expressions are intended to identify
forward-looking statements. These forward-looking statements involve, and are
subject to known and unknown risks, uncertainties and other factors which
could cause Pharmagen actual results, performance (financial or operating) or
achievements to differ from the future results, performance (financial or
operating) or achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more fully
discussed in Pharmagen' filings with the U.S. Securities and Exchange
Commission. All forward-looking statements attributable to Pharmagen herein
are expressly qualified in their entirety by the above-mentioned cautionary
statement. Pharmagen disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by law.

SOURCE Pharmagen, Inc.

Website: http://www.pharmageninc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement